Tchaikapharma High Quality Medicines AD Second Quarter 2024 Earnings: EPS: лв0.014 (vs лв0.026 in 2Q 2023)

Tchaikapharma High Quality Medicines AD (BUL:THQM) Second Quarter 2024 Results

Key Financial Results

• Revenue: лв13.5m (up 11% from 2Q 2023).
• Net income: лв1.34m (down 43% from 2Q 2023).
• Profit margin: 9.9% (down from 19% in 2Q 2023). The decrease in margin was driven by higher expenses.
• EPS: лв0.014 (down from лв0.026 in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tchaikapharma High Quality Medicines AD's share price is broadly unchanged from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Tchaikapharma High Quality Medicines AD (2 shouldn't be ignored!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com